Clik here to view.
EdiGene Announces Publication by Company Scientific Founder in Nature...
BEIJING & CAMBRIDGE, Mass. EdiGene, Inc., a global biotechnology company, today announced its Scientific Founder Wensheng Wei’s lab at Peking University has published a research article in...
View ArticleClik here to view.
Takeda’s TAKHZYRO® (lanadelumab) Approved in Japan for Prophylaxis Against...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda (TSE:4502/NYSE:TAK) today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) for TAKHZYRO® (lanadelumab)...
View ArticleClik here to view.
ウォーターズはバイオ医薬品の質量分析および純度分析用の高速かつ信頼性の高い自動化ソリューションを導入
マサチューセッツ州ミルフォード （ビジネスワイヤ） — ウォーターズコーポレーション (NYSE:WAT) は本日、バイオ医薬品の創薬と開発を支援する新しいソフトウェアおよび分析用カラムを発表しました。waters_connect™ の新しい Waters™ Intact Mass アプリケーションにより、BioAccord™ LC-MS...
View ArticleClik here to view.
Fujirebio Confirms Its Engagement in Blood-based Alzheimer’s Disease...
GENT, Belgium & MALVERN, Pa. & TOKYO H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G β-Amyloid 1-42 Plasma and...
View ArticleClik here to view.
CHA Medical ＆ Bio Group Announces Groundbreaking for its New Cell Gene...
PANGYO, South Korea CHA Medical & Bio Group officially began construction of its Cell Gene Biobank (CGB) facility in Pangyo, South Korea. Investing over $250 million in the project, the new...
View ArticleClik here to view.
Microba Life Sciences and Ginkgo Bioworks Announce Partnership to Discover...
BRISBANE, Australia & BOSTON Microba Life Sciences (ASX: MAP), a precision microbiome science company, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming,...
View ArticleClik here to view.
沃特世推出更快速可靠的自动化解决方案，助力生物药物分子量和纯度分析
美国 马萨诸塞州米尔福德 沃特世公司（纽约证券交易所代码：WAT）近日推出全新软件和分析柱产品，旨在助力生物分子药物发现和开发。使用waters_connect平台新增的Waters Intact Mass应用程序，科学家们能够在BioAccord LC-MS系统上快速确认合成或重组工艺生成的生物分子和杂质分子量，其分析速度可达市场上其他产品的近两倍i。...
View ArticleClik here to view.
Iktos and Teijin Pharma to Co-Develop New Technology for Small Molecule Drug...
PARIS & TOKYO Iktos, a company specialized in Artificial Intelligence (AI) for new drug design, and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business that...
View ArticleClik here to view.
SB623 Demonstrated Sustained Improvement in Motor Impairment up to 48 Weeks...
TOKYO & MOUNTAIN VIEW, Calif. The SanBio Group (SanBio Co., Ltd. of Tokyo, Japan, SanBio, Inc. of Mountain View, California, US, and SanBio Asia Pte. Ltd. of Singapore) (TOKYO: 4592), today...
View ArticleClik here to view.
Microba Appoints Therapeutics Head
BRISBANE, Australia Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) is pleased to announce Professor Trent Munro will be joining the company as Senior Vice President of...
View ArticleClik here to view.
Propanc Biopharma’s CEO Expresses Concern Over Disruption to Cancer Care...
MELBOURNE, Australia Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and...
View ArticleClik here to view.
武田薬品工業：自己株式の取得状況及び取得終了に関するお知らせ
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社は、2021年10月28日開催の取締役会において決議した会社法第459条第１項の規定による定款の定めに基づく自己株式の取得の状況について、下記の通りお知らせします。なお、これをもちまして自己株式の取得は終了しました。 記 取得した自己株式の実績（2022年４月） １． 取得した株式の種類 当社普通株式 ２． 取得した株式の総数...
View ArticleClik here to view.
Takeda Announces Completion of Acquisition of Own Shares
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today provided an update on the status and announced the completion of the acquisition of its own shares, which...
View ArticleClik here to view.
EdiGene Enters Research Collaboration With Peking University Cancer Hospital...
BEIJING & CAMBRIDGE, Mass. EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases...
View ArticleClik here to view.
Propanc Biopharma’s Management Explains Why They Believe Cancer Patients Are...
MELBOURNE, Australia Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and...
View ArticleClik here to view.
武田宣布完成自有股份收购
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TOKYO:4502/NYSE:TAK)（简称“武田”）今天发布了公司的最新动态，并宣布完成自有股份收购，该收购是根据2021年10月28日董事会会议的决议，按照《日本公司法》第459条第1款及其公司章程的规定进行的。 股份收购的详情如下。 2022年4月收购的股份：...
View ArticleClik here to view.
GC Genome Presents AI-Based Liquid Biopsy at the American Association for...
YONGIN, South Korea GC Genome, a leading company in Genomic Diagnostics, is pleased to announce that the company presented the deep learning algorithm that detects and classifies multi-cancer using...
View ArticleClik here to view.
Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda (TSE:4502/NYSE:TAK) today announced that it has received manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare (MHLW)...
View ArticleClik here to view.
組換えコロナウイルス（SARS-CoV-2）ワクチン「ヌバキソビッド®筋注」の日本における初回免疫、および追加免疫を含む製造販売承認取得について
大阪、日本＆ケンブリッジ、マサチューセッツ。 （ビジネスワイヤ） — 当社は、本日、組換えスパイクタンパクを抗原とした新型コロナウイルス感染症ワクチン 「ヌバキソビッド®筋注」（開発コード：TAK-019、以下「ヌバキソビッド」）について、18歳以上を対象として、厚生労働省より初回免疫および追加免疫に対する製造販売承認を取得しましたのでお知らせます。当社は、Novavax,...
View ArticleClik here to view.
GC Signs Definitive Agreement to Acquire US CDMO BioCentriq, Enhancing Global...
YONGIN, SOUTH KOREA & NEWARK, N.J. GC corp. (KOSPI: 005250), the holding (system) company for GC group in South Korea with major operating companies in across healthcare sectors, today announced...
View Article